Last updated: 22 December 2020 at 4:11pm EST

Asset Management, Lp Chen B... Net Worth




The estimated Net Worth of Asset Management, Lp Chen B... is at least $4.1 Million dollars as of 18 December 2020. Asset B owns over 800,000 units of BioAtla stock worth over $4,102,787 and over the last 4 years Asset sold BCAB stock worth over $0.

Asset B BCAB stock SEC Form 4 insiders trading

Asset has made over 3 trades of the BioAtla stock since 2020, according to the Form 4 filled with the SEC. Most recently Asset bought 800,000 units of BCAB stock worth $14,400,000 on 18 December 2020.

The largest trade Asset's ever made was buying 800,000 units of BioAtla stock on 18 December 2020 worth over $14,400,000. On average, Asset trades about 463,333 units every 62 days since 2020. As of 18 December 2020 Asset still owns at least 2,292,060 units of BioAtla stock.

You can see the complete history of Asset B stock trades at the bottom of the page.



Insiders trading at BioAtla

Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B..., and Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.



What does BioAtla do?

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.



What does BioAtla's logo look like?

BioAtla, Inc. logo

Complete history of Asset B stock trades at Avidity Biosciences, Akouos, and BioAtla

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Dec 2020 Asset Management, Lp Chen B...
Buy 800,000 $18.00 $14,400,000
18 Dec 2020
2,292,060
30 Jun 2020 Asset Management, Lp Chen B...
Buy 290,000 $17.00 $4,930,000
30 Jun 2020
789,989
16 Jun 2020 Asset Management, Lp Chen B...
Buy 300,000 $18.00 $5,400,000
16 Jun 2020
2,514,545


BioAtla executives and stock owners

BioAtla executives and other stock owners filed with the SEC include: